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ABSTRACT  
Cancer is a disease involving genetic factors in its pathogenesis. The increase of cell survival as a result of genetic changes, which prevent 
apoptosis such as Bcl2 (B-cell lymphoma-2) activation, will cause the tumor to grow. The overexpression of Bcl2 in small cell lung cancer should 
be inhibited. This study aims to screen natural products that can inhibit Bcl2 overexpression in lung cancer using pharmacophore- and 
molecular docking-based virtual screening to ZINC Natural Product database. The validation of pharmacophore-based virtual screening to the 
three features of the pharmacophore model (2 hydrophobic interactions and 1 hydrogen bond donor) showed that the AUC, EF, Se, Sp, ACC, and 
GH values were 0.57, 3.8, 0.101, 0.957, 0.936, and 0.149, respectively. On the other hand, the validation of molecular docking-based virtual 
screening showed that the RMSD values of Vina Wizard and AutoDock Wizard were 1.3Å and 1.9Å, respectively.  The pharmacophore model 
virtual screening first obtained 6,615 compounds, and then the molecular docking-based virtual screening finally gained 255 compounds whose 
values of ΔG and Ki were lower than those of the native ligand. It was concluded that the virtual screening could yield as many as 255 potential 
anti-lung cancer drug candidates. 
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Cancer is a disease that involves genetic factors in 
its pathogenesis. The process of cell division is 
uncontrolled since the genes that regulate cell growth have 
been damaged. The activation of several oncogenes results 
in the deregulation of cell proliferation, which is often 
associated with apoptosis; and, the result of increased 
apoptosis prevents the tumor to enlarge. However, 
increased cell survival as a result of genetic changes 
prevents apoptosis i.e. activation of B-cell lymphoma (Bcl-
2), thus, causing tumors to grow larger 1.  
Cancer is the leading cause of death worldwide, 
accounting for 8.8 million deaths in 2015. The most 
common causes of death include lung, liver, colorectal, 
stomach, and breast cancers 2. In Indonesia, the prevalence 
of cancer has been quite high, with approximately 1.4 per 
1,000 population, or 347,000 people 3 , and lung cancer 
had the highest percentage of new cases of 23.1% and was 
the highest cause of death 4. 
Bcl2 is a negative regulator of cell death and 
plays an important role in apoptosis regulation. In small 
cell lung cancer, overexpression occurs in Bcl2, and thus, 
Bcl2 activity must be inhibited. Several Bcl2 inhibitors do 
not improve the results of therapy in small cell lung cancer 
patients 5. Therefore, it is necessary to search for new 
active compounds that are projected to be able to inhibit 
Bcl2 overexpression. 
In the discovery of new drugs, drug testing is not 
only carried out in vivo or in vitro but also in silico or by 
computer simulations 6. Virtual screening is a 
computational method that reduces the number of 
chemical compounds that will be identified experimentally 
in a faster time 7. The method of pharmacophore-based 
virtual screening is now commonly used as part of a more 
complex workflow in drug discovery and has been 
successful and widely applied 8. In this study, 
pharmacophore- and molecular docking-based virtual 
screening were used on Zinc natural product database 
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compounds to seek candidates for Bcl2 inhibitor 
compounds as anti-lung cancer. The study first employed 
the pharmacophore-based virtual screening and then 
followed by the docking-based virtual screening. 
RESEARCH METHODS 
Hardware 
The hardware used in this study was a computer 
unit with the specifications of Windows 8.1 Pro 64-bit 
operating system, Intel® CoreTM i7-4790 CPU @ 3.60 GHz 
8 (CPUs), 16 GB of RAM DDR3 memory, and 4 GB 128-bit 
VGA dedicated. 
Protein Structure Preparation of Bcl2 
The structure of the target macromolecule (Bcl-2 
inhibitor) (GDP ID: 3SPF) 9 was obtained from the PDB 
website (www.rcsb.org). 
Ligand Preparation 
The database of the test compounds used for 
virtual screening was the database of natural product 
compounds gained from the ZINC database. The number of 
natural products in the ZINC database was 151,837 
compounds. Each natural product database was grouped 
based on the origin of the country and contains natural 
compounds derived from plants. The ZINC database 
consisted of 12 databases, including AfroDB Natural 
Product, AnalytiCon Discovery NP, Herbal Ingredients In-
Vivo Metabolism, Herbal Ingredients Targets, IBScreen NP, 
Indofine Natural Products, NPACT Database, Nubbe 
Natural Products, Princeton NP, Specs Natural Products, 
TCM Database Taiwan, and UEFS Natural Products. 
The active compounds acting as a positive control 
in the validation of the virtual screening were obtained 
from the website https://www.ebi.ac.uk/chembl/. These 
active compounds were then re-selected following the 
standard value (IC50). Afterward, the IC50 values were 
sorted out by using Microsoft Excel, with the provision that 
the IC50 values should have been smaller than 10,000 nM, 
yielding as many as 40 compounds.  
On the other hand, the decoy compounds used as 
negative control were those inactive compounds acquired 
by searching through Decoy Finder 2.0 software 10. The 
ligand datasets known to be active Bcl-2 inhibitors were 
inserted in the Decoy Finder and later stored in the same 
folder for further processing. There were 1,440 decoy 
compounds generated from the process. 
Pharmacophore-based Virtual Screening 
The pharmacophore modeling utilized the 
LigandScout 4.0 software 11. First, the native ligand 
optimization of the Bcl2 receptor was conducted and then 
stored in a 3D format. The pharmacophore of the 
optimized native ligand was created and also validated. 
The validation was carried out by applying the overall 
pharmacophore features of the native ligand against the 
active and decay compounds. The validation was 
performed by observing the values of the hit compounds 
and the ROC curves which contained the values of AUC of 
more than 0.5 and of EF of over 1.0 8 and also by 
calculating other classic enrichment validation parameters 
such as Se values 12,13, Sp values 13, ACC values 14,15,16, Ya 
values 17, and GH values18. The validated pharmacophore 
models were used for the virtual screening of compounds 
in the ZINC Natural Product Database. 
 
Molecular Docking-based Virtual Screening (PyRx 8.0) 
Molecular docking was carried out by using the 
Pyrx 8.0 software 19 together with Vina Wizard and 
AutoDock Wizard. The macromolecular structure of the 
Bcl2 receptor was downloaded from the Protein Data Bank 
with PDB ID 3SPF. The active site of the protein was made 
following the native ligand binding side of Bcl2 with a grid 
width of 404040 on the XYZ axis with a grid point 
spacing of 0.375 Å. Molecular docking applied as many as 
10 repetitions. Other parameters were used according to 
the default value. The results of the validation of the 
docking method are declared valid if the RMSD value is 
less than 2 Å 20. 
This virtual screening validation was done by 
using the parameters relevant to those in the molecular 
docking of active and decoy compounds. Validation was 
carried out by taking into account the validation parameter 
values as those in the pharmacophore validation. The ROC 
curves were created on the website http://rocr.bioinf.mpi-
sb.mpg.de/ 21. The validated model was then employed for 
virtual screening of compounds of the ZINC natural 
product database from the previous screening. The result 
was further examined by virtual docking-based screening. 
RESULTS AND DISCUSSION 
Virtual screening (VS) is a computational filter to 
reduce the size of a chemical library that will be identified 
experimentally and offers opportunities to quickly reduce 
the time and effort associated with identification 7. VS is 
described as the use of high-performance computational 
calculations in analyzing a database of many chemical 
compounds in order to identify the probability of drug 
candidates 22. There are two fundamental approaches to 
virtual screening: the ligand-based approach and the 
receptor-based approach. The ligand-based approach aims 
to identify molecules with physical and chemical 
similarities (pharmacophore-based, descriptor-based) 
against identified ligands that tend to interact with targets. 
The structure-based pharmacophore modeling approach 
uses information about protein-ligand interactions 
obtained from experimental 3D structures in order to 
produce a model 23. 
Pharmacophore-based Virtual Screening 
Prior to virtual screening, the validation of the 
pharmacophore features was employed first. The target 
was Bcl2 receptor (GDP code: 3SPF) with native ligand 4- 
(4-chlorophenyl)-1-[(3S) -3,4-dihydroxybutyl]-N-[3-(4-
methylpiperazin-1-yl) propyl] -3-phenyl-1H-pyrrole-2-
carboxamide (C29 H37 Cl N4 O3) with a resolution of 1.7 Å. 
After optimization of the ligand bound to the Bcl2 receptor, 
the pharmacophore features from the ligand were 
generated. Only four pharmacophore features were 
obtained including 3 hydrophobic interactions and 1 
hydrogen bond donor (Figure 1a.). These pharmacophore 
features were then validated with active and decoy 
datasets (Table 1). The first and second models gained 
were good because their AUC and EF values met the 
requirements. A good AUC value has AUC≥ 0.5, a good EF 
value has EF≥ 0.1, a good Se value equals to 1, a good Sp 
value equals to 1, and for the GH value, the higher the 
value, the better 8. Therefore, by looking at the value of 
these classic enrichment parameters, the model one was 
created and used as a virtual pharmacophore model for 
screening the natural product database. This first model 
consisted of 3 pharmacophore features used later for 
virtual screening: 2 hydrophobic interactions and 1 
hydrogen bond donor.  
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Table 1 Validation of pharmacophore features 
Model AUC 100% EF 100% Se Sp ACC Ya GH 
1 0.57 3.8 0.101 0.957 0.936 0.175 0.149 
2 0.67 2.6 0.069 0.832 0.809 0.45 0.029 
3 0.48 0.5 0.014 0.901 0.878 0.05 0.021 
4 0.36 0 0.012 0.535 0.526 0.2 0.082 
5 0.49 0 0 0.982 0.955 0 0 
AUC > 0.5; EF > 1; Se=1; Sp=1; GH= the higher the value, the better 
 
                                               
 
  
a b c 
Figure 1. Pharmacophore features of native ligand (a), validated pharmacophore features (b), and ROC curves for the first 
model (c). 
 
Here, the natural product compounds obtained 
from the site http://www.zinc.docking.org were firstly 
screened consisting of 12 databases with a total of 151,837 
compounds. The virtual screening utilized the model one, 
as the validated pharmacophore model, resulting in 6,615 
compounds. However, the outputs were still considered 
too many candidates; thus, further screening was needed 
to obtain fewer compounds. 
Molecular Docking-based Virtual Screening  
The next stage of the filtering process involved 
docking each molecule in the database into the target 
binding area. The docking process comprised sampling the 
coordinate space of the binding location and printing every 
possible ligand pose, which was later taken as the 
predicted binding mode for the compound 24. Validation of 
the docking method was applied by re-docking the native 
ligand and Bcl2 target receptor. 
The molecular docking with the test compounds 
using PyRx software was divided into 2 phases. Phase one 
employed Vina Wizard while phase two employed 
AutoDock Wizard. The re-docking processes with both 
Vina Wizard and Autodock Wizard were done in PyRx 8.0 
software. Grid Box settings used for the Vina Wizard 
included X: 19.09, Y: 23.64, and Z: 21.33, whereas Grid 
Spacing used 1.0 Å with Grid Center X: 29.54, Y: 13.13, and 
Z: 21.68. Meanwhile, those for Autodock Wizard included 
Grid Box X: 72, Y: 67, and Z: 68, and Grid Spacing of 1.0 Å 
with Grid Center X: 28.94, Y: 10.29, and Z: 22.49. The 
RSMD values for Vina Wizard and Autodock Wizard were 
1.3 Å and 1.99 Å, respectively, and the docking method 








a b c 
Figure 2 Visualization of Bcl 2 receptor (PDB code) (a) re-docking results with Vina Wizard (b), and re-docking results with 
Autodock Wizard (c) to validate the docking method. 
Note: pink for the native ligand and blue for the ligand of re-docking 
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Figure 3 ROC curves of validation results of virtual 
screening method with Vina Wizard (a) and Autodock 
Wizard (b) for virtual validation of docking-based 
screening. 
Note: A total of 1,480 compounds with 40 active and 1,440 
inactive compounds (decoys) 
Further, virtual screening was carried out by 
using PyRx, and then virtual screening validation by using 
active and decoy compounds. Validation parameters for 
the Vina Wizard were AUC and EF values of 0.592 and 37.0, 
respectively, while those for the Autodock Wizard were 
AUC and EF values of 0.693 and 37.0, respectively. These 
findings indicated that the virtual screening validation in 
both the Vina Wizard and Autodock Wizard were valid 
enough since they met the requirements; therefore, 
screening could be carried out for the test compounds. 
The screening results obtained at the Vina 
Wizard were 2,473 compounds, whose binding energy 
values were smaller than native ligand. These results were 
further screened by using the AutoDock Wizard, yielding 
255 test compounds (Table 2). 
Identification of the best test compounds 
The screening results of the test compounds 
obtained were further analyzed in order to discover the 
best compounds. This analysis could be seen from the 
compounds with the smallest binding energy values, aside 
from the values of the inhibition constant. The values of 
binding energy and inhibition constant which were lower 
than the native ligand indicated that the binding strength 
between the ligands from the screening results and the 
receptor was better. The values of binding energy yielded 
255 compounds, and then this result was later sorted out 
according to the values of the inhibition constant. In the 
native ligand, the inhibition constant value obtained was 
128.81 µM whereas these 255 compounds had smaller 
inhibition constant values. The smallest value of the 
binding energy of the inhibition constant earned by the 
ligand with the code tc259, having a BE value of ˗11.02 
kcal/mol and Ki of 8.33 nM. Another analysis performed 
was by using ligand interactions between amino acid 
residues of Bcl2 and test compounds (Figure 3). In the 
native ligand, there were hydrogen bonds on amino acid 
residues GLU129, making this a reference for obtaining the 
candidate compounds that interacted with the Bcl2 
receptor. The interactions occurring between the ligands 
and the Bcl2 receptor included hydrogen bond, 
hydrophobic interaction, and Van der Waals interaction. 
 
 






based VS  
Docking-based VS 
 Vina Wizard AutoDock Wizard 
 1. Afronp 884 66 21 4 
 2. Acdiscnp 11,217 786 54 28 
 3. Himnp 652 36 20 10 
 4. Hitnp 801 29 14 8 
 5. Indofinenp 142 8 0 0 
 6. Ibsnp 84,099 2,095 1,199 81 
 7. Npactnp 1,421 94 19 16 
 8. Nubbenp 584 28 12 10 
 9. Princetonnp 14,084 312 38 31 
 10. Specsnp 1,488 42 6 4 
 11. Tcmnp 35,993 3,105 1,081 58 
 12. Uefsnp 472 14 9 5 
 Total 151,837 6,615 2,473 255 
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Figure 4 Interactions of (a) native ligand of re-docking results (b) test ligands with Bcl2 receptor 
 
CONCLUSIONS 
The pharmacophore-based virtual screening involving 
hydrophobic interactions and hydrogen bonds was able to 
eliminate approximately 85.64% of compounds. Further, the 
docking-based virtual screening was capable of diminishing 
about 96.15% of compounds predicted to inhibit Bcl2 
protein overexpression. The interactions between the best 
test compounds and the Bcl2 receptor included Van der 
Waals interaction, hydrogen bond, and hydrophobic 
interaction. 
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